These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 20854072)

  • 1. Aurora-A expression, hormone receptor status and clinical outcome in hormone related cancers.
    Das K; Lorena PD; Ng LK; Shen L; Lim D; Siow WY; Narasimhan K; Teh M; Choolani M; Putti TC; Salto-Tellez M
    Pathology; 2010; 42(6):540-6. PubMed ID: 20854072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression patterns of Aurora A and B kinases, Ki-67 and the estrogen and progesterone receptors determined using an endometriosis tissue microarray model.
    Calcagno A; Grassi T; Mariuzzi L; Marzinotto S; Londero AP; Orsaria M; Beltrami CA; Marchesoni D
    Hum Reprod; 2011 Oct; 26(10):2731-41. PubMed ID: 21840910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Value of steroid hormone receptors as prognostic factors in breast, ovarian and endometrial cancer].
    von Minckwitz G; Kaufmann M
    Gynakologe; 1993 Apr; 26(2):100-6. PubMed ID: 8508979
    [No Abstract]   [Full Text] [Related]  

  • 4. Expression of coxsackie-adenovirus receptor is related to estrogen sensitivity in breast cancer.
    Auer D; Reimer D; Porto V; Fleischer M; Roessler J; Wiedemair A; Marth C; Müller-Holzner E; Daxenbichler G; Zeimet AG
    Breast Cancer Res Treat; 2009 Jul; 116(1):103-11. PubMed ID: 18618240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer.
    Lee P; Rosen DG; Zhu C; Silva EG; Liu J
    Gynecol Oncol; 2005 Mar; 96(3):671-7. PubMed ID: 15721410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aurora kinases as prognostic biomarkers in ovarian carcinoma.
    Mendiola M; Barriuso J; Mariño-Enríquez A; Redondo A; Domínguez-Cáceres A; Hernández-Cortés G; Pérez-Fernández E; Sánchez-Navarro I; Vara JA; Suárez A; Espinosa E; González-Barón M; Palacios J; Hardisson D
    Hum Pathol; 2009 May; 40(5):631-8. PubMed ID: 19157502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays.
    Latil A; Bièche I; Vidaud D; Lidereau R; Berthon P; Cussenot O; Vidaud M
    Cancer Res; 2001 Mar; 61(5):1919-26. PubMed ID: 11280747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor 8 expression in breast carcinoma: associations with androgen receptor and prostate-specific antigen expressions.
    Tanaka A; Kamiakito T; Takayashiki N; Sakurai S; Saito K
    Virchows Arch; 2002 Oct; 441(4):380-4. PubMed ID: 12404063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
    Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
    Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer.
    Nogi H; Kobayashi T; Suzuki M; Tabei I; Kawase K; Toriumi Y; Fukushima H; Uchida K
    Oncol Rep; 2009 Feb; 21(2):413-7. PubMed ID: 19148516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
    Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathological and biological features of breast cancer in young females and their relationship with prognosis].
    Meng J; Lang RG; Fan Y; Fu L
    Zhonghua Zhong Liu Za Zhi; 2007 Apr; 29(4):284-8. PubMed ID: 17760256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of osteopontin in patients with triple-negative breast cancer.
    Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
    Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
    Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
    Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD44s expression, in benign, borderline and malignant tumors of ovarian surface epithelium. Correlation with p53, steroid receptor status, proliferative indices (PCNA, MIB1) and survival.
    Zagorianakou N; Stefanou D; Makrydimas G; Zagorianakou P; Briasoulis E; Karavasilis B; Agnantis NJ
    Anticancer Res; 2004; 24(3a):1665-70. PubMed ID: 15274338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.